Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Keith

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and PrimateJohn M Keith, Rich Apodaca, Mark Tichenor, et al.
Bioorganic & Medicinal Chemistry Letters|February 12, 2014
1-Aryl-2-((6-aryl)pyrimidin-4-yl)amino)ethanols as competitive inhibitors of fatty acid amide hydrolaseJohn M Keith, Natalie Hawryluk, Richard L Apodaca, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2014
Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolaseJohn M Keith, William M Jones, Joan M Pierce, et al.
Bioorganic & Medicinal Chemistry Letters|May 19, 2016
The SAR of brain penetration for a series of heteroaryl urea FAAH inhibitorsJohn M Keith, Mark S Tichenor, Richard L Apodaca, et al.
Bioorganic & Medicinal Chemistry Letters|November 13, 2012
Heteroaryl urea inhibitors of fatty acid amide hydrolase: structure-mutagenicity relationships for arylamine metabolitesMark S Tichenor, John M Keith, William M Jones, et al.
Bioorganic & Medicinal Chemistry Letters|November 28, 2006
Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitorsMichael A Letavic, John M Keith, Jill A Jablonowski, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical developmentMichael A Letavic, Leah Aluisio, John R Atack, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
ACS Medicinal Chemistry Letters|June 6, 2014
Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and PrimateJohn M Keith, Rich Apodaca, Mark Tichenor, et al.
Bioorganic & Medicinal Chemistry Letters|February 12, 2014
1-Aryl-2-((6-aryl)pyrimidin-4-yl)amino)ethanols as competitive inhibitors of fatty acid amide hydrolaseJohn M Keith, Natalie Hawryluk, Richard L Apodaca, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2014
Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolaseJohn M Keith, William M Jones, Joan M Pierce, et al.
Bioorganic & Medicinal Chemistry Letters|May 19, 2016
The SAR of brain penetration for a series of heteroaryl urea FAAH inhibitorsJohn M Keith, Mark S Tichenor, Richard L Apodaca, et al.
Bioorganic & Medicinal Chemistry Letters|November 13, 2012
Heteroaryl urea inhibitors of fatty acid amide hydrolase: structure-mutagenicity relationships for arylamine metabolitesMark S Tichenor, John M Keith, William M Jones, et al.
Bioorganic & Medicinal Chemistry Letters|November 28, 2006
Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitorsMichael A Letavic, John M Keith, Jill A Jablonowski, et al.
Bioorganic & Medicinal Chemistry Letters|June 22, 2010
Pre-clinical characterization of aryloxypyridine amides as histamine H3 receptor antagonists: identification of candidates for clinical developmentMichael A Letavic, Leah Aluisio, John R Atack, et al.
Pageof 3